Physician profile
Gerald C Moore
NPI 1770531121
$5,233.39
in general payments reported to CMS, 2019-2025
26 companies · $704 in 2025
The $704 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $527 · 2021: $717 · 2022: $841 · 2023: $1,095 · 2024: $977 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,738 · Education: $37.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,738.38 |
| Education | $37.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,350.05 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $1,046.31 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $566.55 | 2019-2024 | Xembify |
| Genzyme Corporation | $325.85 | 2019-2025 | |
| Glaxosmithkline, LLC. | $316.36 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $285.86 | 2020-2025 | |
| Covis Pharma Gmbh | $247.88 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $233.64 | 2019-2025 | |
| Amgen INC. | $140.33 | 2022-2024 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $137.15 | 2020-2024 | Takhzyro |
| Teva Pharmaceuticals USA, INC. | $105.13 | 2020-2023 | |
| Csl Behring | $92.83 | 2023-2025 | Hizentra, Privigen |
| Octapharma USA, INC. | $56.32 | 2020-2023 | Cutaquig |
| Blueprint Medicines Corporation | $42.74 | 2024-2025 | Ayvakit |
| Optinose US, INC. | $37.44 | 2023-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $33.80 | 2020-2022 | |
| Alk-Abello, INC | $30.73 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $26.72 | 2022 | |
| Lilly USA, LLC | $25.79 | 2024 | Ebglyss |
| Bio Products Laboratory USA, INC. | $25.12 | 2022 | |
| Merck Sharp & Dohme LLC | $24.95 | 2023 | |
| Shire North American Group INC | $19.86 | 2019 | |
| Mylan Specialty L.P. | $19.29 | 2020 | |
| Azurity Pharmaceuticals, INC. | $17.43 | 2025 | Alvesco |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.27 | 2020 | |
| Organon LLC | $10.99 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.